Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Emerging therapeutic targets for advanced colorectal cancer

Armando Orlandi • 12 Sep 2022
ESMO 2022
Colorectal Cancer Gastrointestinal Cancer
ERMES

Armando Orlandi, MD, PhD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, discusses the translational analyses conducted in the ERMES study (NCT02484833), and the role that emerging theraputic targets are playing in the treatment landscape of advanced colorectal cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Armando Orlandi

0:28
Unanswered questions regarding the use of first-line therapy in mCRC
Armando Orlandi • 12 Sep 2022
2:00
ERMES: FOLFIRI/cetuximab followed by cetuximab inferior to SOC in RAS & BRAF wt mCRC
Armando Orlandi • 12 Sep 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals